Ash and colleagues have recently reported an alternative flow cytometry method which identifies tumor cells expressing both CD99 and CD90 but which are negative for a hematopoietic panel including CD45, CD3, CD14, CD16, and CD19. This evidence concerns the gene CD99 and neoplasm.